Researchers Find New Therapeutic Approaches For Treating Tuberculosis

Tubercluosis is a leading disease all around the world. Read ahead to know about the new therapeutic approaches for treating it.

Tanya Srivastava
Written by: Tanya SrivastavaPublished at: Jul 30, 2022Updated at: Jul 30, 2022
Researchers Find New Therapeutic Approaches For Treating Tuberculosis

Tubercluosis is a leading disease all around the world. It affects almost 25% of the population worldwide. Drug-resistant strains have made it difficult to treat the infection. According to professor Helen Zgurskaya of the University of Oklahoma and  his new research on developing a new theraputic approach to the disease. 

The comprehensive findings of the research were published in Proceedings of the National Academy of Sciences. The study's prime focus was on understanding how recently discovered new inhibitors kill the pathogen.

Accoring to the lead researcher Zgurskaya, "This is one of the scariest infectious diseases affecting billions of people worldwide. Like many other bacterial infections, it is becoming more resistant to antibiotics. Currently, the treatment requires a combination of antibiotics taken by patients for six months, but now imagine that the disease does not respond to the treatment. We are out of therapeutic options for this infection, and we need new drugs."

"Like many other bacterial infections, it is becoming more resistant to antibiotics. Currently, the treatment requires a combination of antibiotics taken by patients for six months, but now imagine that the disease does not respond to the treatment. We are out of therapeutic options for this infection, and we need new drugs," he further added.

New Therapeutic Approaches For Treating Tuberculosis

Also read: Plant-Based Meat Is Healthier Than Animal Products, Says Study

Researchers also found that all reconstituted proteins facilitate proton translocation across membranes but studied MmpL3 analogs differ dramatically in their responses to pH and interactions with substrate mimics and indole-2-carboxamide inhibitors. Their results further elucidate that some inhibitors abolish the transport activity of MmpL3 hence analoging by inhibition of proton translocation.

Zgurskaya also expects that the next step would be to use the methods and techniques the team developed for analysing other inhibitors to correctly identify those that are most effective. The researchers are hopeful that then it will go into the clinical trials.

Disclaimer